Shares of Bio-Path Holdings, Inc. (BPTH) soared 90% on Thursday after it announced the successful completion of the higher dose second cohort in phase 1/1b clinical trial of BP1002 in refractory/relapsed Acute Myeloid Leukemia (AML) patients.
BPTH is currently trading at $6.13, up $2.90 or 89.78%, on the Nasdaq. The stock opened its trading at $5.41 after closing Wednesday at $3.23. The stock has traded between $2.71 and $44.80 in the past 52-week period.
Bio-Path Holdings announced the completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
"We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options."
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.